Candida albicans protein

Candida albicans protein is a broad term encompassing the entire proteome of the opportunistic fungal pathogen Candida albicans (UniProt, 2024). In the context of drug development, this term is non-specific and typically refers to a variety of essential fungal proteins that serve as targets for antifungal agents. The most prominent targets include Lanosterol 14-alpha demethylase (Erg11p), which is inhibited by azoles to disrupt ergosterol synthesis, and 1,3-beta-glucan synthase (Fks1p), which is targeted by echinocandins to impair cell wall integrity (StatPearls, 2023; NCBI, 2022). Other important proteins include secreted aspartic proteases (SAPs) and adhesins like the Agglutinin-like sequence (Als) proteins, which are critical for host colonization and virulence (PubMed, 2021). Because C. albicans is a eukaryotic organism, therapeutic strategies must focus on proteins that are either unique to fungi or sufficiently different from human homologs to ensure selective toxicity (Nature Reviews Microbiology, 2017). Consequently, 'Candida albicans protein' is not a single therapeutic target but a category of potential molecular sites for treating candidiasis.

Other names

Candida albicans proteomeC. albicans antigensFungal proteins (C. albicans)

Antifungal drugs target specific Candida albicans proteins to disrupt vital cellular processes. Azoles (e.g., fluconazole) bind to the heme iron of Lanosterol 14-alpha demethylase (Erg11p), inhibiting the production of ergosterol, a key component of the fungal cell membrane (NCBI, 2022). Echinocandins (e.g., caspofungin) inhibit the 1,3-beta-glucan synthase complex, preventing the synthesis of 1,3-beta-D-glucan, an essential structural component of the fungal cell wall (StatPearls, 2023). Flucytosine is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA/RNA synthesis (PubMed, 2021).